These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 36612249)
1. Present and Future Role of Immune Targets in Acute Myeloid Leukemia. Damiani D; Tiribelli M Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612249 [TBL] [Abstract][Full Text] [Related]
2. Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. Michelozzi IM; Kirtsios E; Giustacchini A Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34198742 [TBL] [Abstract][Full Text] [Related]
3. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches. Thakral D; Gupta R; Khan A Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219 [TBL] [Abstract][Full Text] [Related]
4. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. Venugopal S; Daver N; Ravandi F Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233 [TBL] [Abstract][Full Text] [Related]
5. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia. Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662 [TBL] [Abstract][Full Text] [Related]
6. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. Al-Mawali A; Gillis D; Lewis I J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508 [TBL] [Abstract][Full Text] [Related]
7. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758 [TBL] [Abstract][Full Text] [Related]
8. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052 [TBL] [Abstract][Full Text] [Related]
9. Location First: Targeting Acute Myeloid Leukemia Within Its Niche. Pievani A; Biondi M; Tomasoni C; Biondi A; Serafini M J Clin Med; 2020 May; 9(5):. PubMed ID: 32443460 [TBL] [Abstract][Full Text] [Related]
10. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting. Chen Y; Li J; Xu L; Găman MA; Zou Z Cell Death Discov; 2022 Sep; 8(1):397. PubMed ID: 36163119 [TBL] [Abstract][Full Text] [Related]
11. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765 [TBL] [Abstract][Full Text] [Related]
12. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741 [TBL] [Abstract][Full Text] [Related]
13. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365 [TBL] [Abstract][Full Text] [Related]
14. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589 [TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934 [TBL] [Abstract][Full Text] [Related]
17. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944 [TBL] [Abstract][Full Text] [Related]
18. A general view of CD33 Fathi E; Farahzadi R; Sheervalilou R; Sanaat Z; Vietor I Blood Res; 2020 Mar; 55(1):10-16. PubMed ID: 32269970 [TBL] [Abstract][Full Text] [Related]
19. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Kubicka E; Lum LG; Huang M; Thakur A Front Immunol; 2022; 13():899468. PubMed ID: 36389764 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. Schürch CM Front Oncol; 2018; 8():152. PubMed ID: 29868474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]